Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis

BACKGROUND: Dupilumab is a monoclonal antibody against interleukin 4 receptor alpha and has proven to be clinically effective in treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, a certain number of patients are non- or partial responders. This study aims to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Brkic, Faris F., Liu, David T., Rücklinger, Iris, Campion, Nicholas James, Bartosik, Tina Josefin, Vyskocil, Erich, Stanek, Victoria, Tu, Aldine, Gangl, Katharina, Schneider, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676571/
https://www.ncbi.nlm.nih.gov/pubmed/38007429
http://dx.doi.org/10.1186/s40463-023-00660-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676571/
https://www.ncbi.nlm.nih.gov/pubmed/38007429
http://dx.doi.org/10.1186/s40463-023-00660-7

Ejemplares similares